Pharmacotherapy of atrial fibrillation

Jan Nemec, Win Kuang Shen

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Atrial fibrillation (AF) remains a widespread health problem and the drugs available for its treatment suffer from several drawbacks, including potentially lethal proarrhythmia, serious non-cardiac toxicity and limited efficacy. The evidence for efficacy of currently available anti-arrhythmic agents for sinus rhythm restoration and maintenance is reviewed, with emphasis on randomised trials when available. The current approach to thromboembolism prophylaxis in AF is summarised. 1999

Original languageEnglish (US)
Pages (from-to)81-96
Number of pages16
JournalExpert Opinion on Pharmacotherapy
Issue number1
StatePublished - Jan 1 1999


  • Anti-arrhythmic drugs
  • Anticoagiilation
  • Atrial fibrillation
  • Thromboembolism
  • Treatment

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Pharmacotherapy of atrial fibrillation'. Together they form a unique fingerprint.

Cite this